Adaptive Biotechnologies ADPT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's financing cash flow?
- Adaptive Biotechnologies (ADPT) reported financing cash flow of $7.5M in Q1 2026.
- How has Adaptive Biotechnologies's financing cash flow changed year-over-year?
- Adaptive Biotechnologies's financing cash flow increased by 37.6% year-over-year, from $5.45M to $7.5M.
- What is the long-term trend for Adaptive Biotechnologies's financing cash flow?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's financing cash flow has grown at a 2.9% compound annual growth rate (CAGR), from $27.15M to $30.4M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.